Vancomycin in the treatment of Inflammatory Bowel Disease: There is a role beyond Clostridioides difficile infection.

Simple item page
dc.contributor.authorPaula Calderón
dc.contributor.authorOriana M. Damas
dc.contributor.authorPaulina Núñez
dc.contributor.authorRodrigo Quera
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T21:16:16Z
dc.date.available2026-03-22T21:16:16Z
dc.date.issued2023
dc.description.abstractThe development of new biological agents and small molecules has revolutionized the treatment of Inflammatory Bowel Disease (IBD). However, many patients do not respond or gradually lose their response, necessitating the search for other therapeutic strategies (1). In this clinical case, we describe the evolution of a patient with difficult-to-manage Crohn's Disease (CD) who was treated with oral vancomycin.
dc.identifier.doi10.17235/reed.2023.9942/2023
dc.identifier.urihttps://doi.org/10.17235/reed.2023.9942/2023
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/86944
dc.language.isoen
dc.publisherArán Ediciones
dc.relation.ispartofRevista Española de Enfermedades Digestivas
dc.sourceUniversidad de Los Andes, Chile
dc.subjectMedicine
dc.subjectClostridioides
dc.subjectInflammatory bowel disease
dc.subjectVancomycin
dc.subjectDisease
dc.subjectIntensive care medicine
dc.subjectInflammatory Bowel Diseases
dc.subjectInternal medicine
dc.subjectGastroenterology
dc.titleVancomycin in the treatment of Inflammatory Bowel Disease: There is a role beyond Clostridioides difficile infection.
dc.typeletter

Files

Collections

Artículo Científico Publicado